免疫性および構成性プロテアゾームの結晶構造は,基板および阻害剤特異性の違いを明らかにします
Eva M Huber1, Michael Basler, Ricarda Schwab
1Center for Integrated Protein Science at the Department Chemie, Lehrstuhl für Biochemie, Technische Universität München, Garching D-85747, Germany.
Cell
|February 21, 2012
まとめ
マウスのプロテアソームと免疫プロテアソームの構造を決定し,抑制剤PR-957が免疫プロテアソームをどのように選択的に標的としているかを明らかにしました. この発見は,がんや自己免疫疾患に対する新薬の設計に役立ちます.
科学分野:
- バイオケミストリー バイオケミストリー
- 構造生物学 構造生物学とは
- 免疫学 免疫学とは
背景:
- 抗原の表示に不可欠なプロテアゾームは,構成的および免疫プロテアゾームの形態に存在し,明確な触媒的サブユニットを持っています.
- これらのサブユニットは,メジャー・ヒストコンパティビリティ・コンプレックスクラスI (MHC-I) の分子によって提示されるペプチドレパートリーに影響を与えます.
研究 の 目的:
- PR-957.7による免疫プロテアソームの選択的阻害の構造的基礎を解明する.
- 構成プロテアソームと免疫プロテアソームの構造的な違いを理解する.
主な方法:
- 2.9 Åの解像度でマウスの構成プロテアソームと免疫プロテアソーム (PR-957となし) のX線結晶撮影.
- イーストプロテアソーム:PR-957複合体の時間分解構造分析.
主要な成果:
- 免疫プロテアソームサブユニットβ5i/LMP7の新しい触媒特性が特定されました.
- PR-957は,S1ポケットの形状の違いにより,β5cではなくβ5iサブユニットに選択的に結合します.
- リガンドドッキングは,特に反応性ヘッドグループとP1サイドチェーンを通じて発生します.
結論:
- 構造的な洞察は,免疫プロテアゾーム選択性阻害剤の合理的な設計をサポートします.
- これらの阻害剤は,がんや自己免疫疾患などの異常なサイトカイン生成に関連する疾患の治療に潜在的に役立ちます.
さらに関連する動画
関連する概念動画
Enzymes
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Protein-protein Interfaces
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome Structure
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...


